23 reports of this reaction
2.6% of all ISOPROTERENOL HYDROCHLORIDE reports
#5 most reported adverse reaction
ELECTROCARDIOGRAM QT PROLONGED is the #5 most commonly reported adverse reaction for ISOPROTERENOL HYDROCHLORIDE, manufactured by Cipla USA Inc.. There are 23 FDA adverse event reports linking ISOPROTERENOL HYDROCHLORIDE to ELECTROCARDIOGRAM QT PROLONGED. This represents approximately 2.6% of all 894 adverse event reports for this drug.
Patients taking ISOPROTERENOL HYDROCHLORIDE who experience electrocardiogram qt prolonged should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ELECTROCARDIOGRAM QT PROLONGED is a less commonly reported adverse event for ISOPROTERENOL HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to electrocardiogram qt prolonged, the following adverse reactions have been reported for ISOPROTERENOL HYDROCHLORIDE:
The following drugs have also been linked to electrocardiogram qt prolonged in FDA adverse event reports:
ELECTROCARDIOGRAM QT PROLONGED has been reported as an adverse event in 23 FDA reports for ISOPROTERENOL HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ELECTROCARDIOGRAM QT PROLONGED accounts for approximately 2.6% of all adverse event reports for ISOPROTERENOL HYDROCHLORIDE, making it a notable side effect.
If you experience electrocardiogram qt prolonged while taking ISOPROTERENOL HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.